fda compounding tirzepatide Compounded Injections $100 FDA says compounding pharmacies can

insulin or sulfonylureas) can raise your risk of experiencing hypoglycemia (low blood sugar)

Hypertension 46 , 326332 (2005)

The metabolic implications are significant

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide act on appetite, satiety, and gastric emptying, supported by STEP (semaglutide, NEJM 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024)

However, such Fc-engineering may also negatively influence effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC) 9,27